Ikena Oncology, Inc. (IKNA)
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
IKNA Insider Trading Activity
IKNA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Related Transactions
About Ikena Oncology, Inc.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor …
Insider Activity of Ikena Oncology, Inc.
Over the last 12 months, insiders at Ikena Oncology, Inc. have bought $0 and sold $0 worth of Ikena Oncology, Inc. stock.
On average, over the past 5 years, insiders at Ikena Oncology, Inc. have bought $8.94M and sold $797,472 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 23,419 shares for transaction amount of $86,884 was made by Bonita David P () on 2022‑06‑22.
List of Insider Buy and Sell Transactions, Ikena Oncology, Inc.
| 2022-06-22 | Bonita David P | 23,419 0.0656% | $3.71 | $86,884 | +14.75% | |||
| 2022-06-22 | OrbiMed Genesis GP LLC | 66,806 0.1792% | $3.55 | $237,161 | +14.75% | |||
| 2022-01-11 | Sale | Zhang Xiaoyan Michelle | Chief Scientific Officer | 964 0.0026% | $12.00 | $11,568 | -63.56% | |
| 2021-12-14 | Sale | FORMELA JEAN FRANCOIS | director | 5,959 0.0217% | $14.00 | $83,426 | -63.59% | |
| 2021-12-14 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 5,959 0.0217% | $14.00 | $83,426 | -63.59% | |
| 2021-12-13 | Sale | FORMELA JEAN FRANCOIS | director | 8,330 0.0307% | $14.64 | $121,951 | -64.74% | |
| 2021-12-13 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 8,330 0.0307% | $14.64 | $121,951 | -64.74% | |
| 2021-12-10 | Sale | FORMELA JEAN FRANCOIS | director | 11,989 0.0457% | $15.03 | $180,195 | -64.33% | |
| 2021-12-10 | Sale | Atlas Venture Fund XI, L.P. | 10 percent owner | 11,989 0.0457% | $15.03 | $180,195 | -64.33% | |
| 2021-12-10 | Sale | Zhang Xiaoyan Michelle | Chief Scientific Officer | 1,000 0.0037% | $14.76 | $14,760 | -64.33% | |
| 2021-03-30 | ORBIMED ADVISORS LLC | director | 423,400 6.8729% | $16.00 | $6.77M | -49.34% | ||
| 2021-03-30 | Bonita David P | director | 423,400 6.8729% | $16.00 | $6.77M | -49.34% | ||
| 2021-03-30 | FORMELA JEAN FRANCOIS | director | 125,000 2.0291% | $16.00 | $2M | -49.34% | ||
| 2021-03-30 | Atlas Venture Fund XI, L.P. | 10 percent owner | 125,000 2.0291% | $16.00 | $2M | -49.34% |
Insider Historical Profitability
| Bonita David P | 1936097 4.8092% | $2.59M | 2 | 0 | <0.0001% | |
| OrbiMed Genesis GP LLC | 1912678 4.751% | $2.56M | 1 | 0 | +14.75% | |
| ORBIMED ADVISORS LLC | director | 1845872 4.5851% | $2.47M | 1 | 0 | <0.0001% |
| FORMELA JEAN FRANCOIS | director | 1241935 3.0849% | $1.66M | 1 | 3 | <0.0001% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 1241935 3.0849% | $1.66M | 1 | 3 | <0.0001% |
Historical Insider Profitability vs. Competitors
$81,638,324 | 48 | 7.58% | $49.31M | |
$459,011,221 | 33 | 33.04% | $57.94M | |
$18,274,594 | 22 | -26.07% | $49.68M | |
$26,736,140 | 20 | -18.64% | $54.85M | |
$47,863,113 | 17 | -22.07% | $56.72M |
IKNA Institutional Investors: Active Positions
| Increased Positions | 16 | +19.75% | 6M | +16.68% |
| Decreased Positions | 32 | -39.51% | 3M | -7.23% |
| New Positions | 7 | New | 3M | New |
| Sold Out Positions | 12 | Sold Out | 947,337 | Sold Out |
| Total Postitions | 65 | -19.75% | 38M | +9.45% |
IKNA Ownership Change vs Market
Institutional Investor Ownership
| Orbimed Advisors Llc | $13,277.00 | 24.77% | 9.91M | 0 | 0% | 2024-12-31 |
| Atlas Venture Life Science Advisors, Llc | $6,724.00 | 12.55% | 5.02M | 0 | 0% | 2024-12-31 |
| Blue Owl Capital Holdings Lp | $5,482.00 | 10.23% | 4.09M | 0 | 0% | 2024-12-31 |
| Bvf Inc/Il | $5,369.00 | 10.02% | 4.01M | -762,600 | -15.99% | 2024-12-31 |
| Bml Capital Management, Llc | $4,805.00 | 8.97% | 3.59M | +3M | +395.77% | 2024-12-31 |
| Omega Fund Management, Llc | $3,014.00 | 5.62% | 2.25M | 0 | 0% | 2024-12-31 |
| Gilead Sciences, Inc. | $2,691.00 | 5.02% | 2.01M | +2M | New | 2024-12-31 |
| Vanguard Group Inc | $1,855.00 | 3.46% | 1.38M | 0 | 0% | 2024-12-31 |
| Adage Capital Partners Gp, L.L.C. | $1,072.00 | 2% | 800,000 | -187,900 | -19.02% | 2024-12-31 |
| Nea Management Company, Llc | $804.00 | 1.5% | 600,063 | 0 | 0% | 2024-12-31 |